Prophylaxis of hepatitis B virus recurrence after liver transplantation.
Testino
Gianni
G
Borro
Paolo
P
Sumberaz
Alessandro
A
D000998:Antiviral Agents / Q000008:administration & dosage* / Q000191:economics; D003362:Cost-Benefit Analysis; D004279:DNA, Viral / Q000097:blood; D016527:Drug Costs; D004359:Drug Therapy, Combination; D005260:Female; D017048:Health Care Costs; D006509:Hepatitis B / Q000175:diagnosis / Q000191:economics / Q000276:immunology / Q000517:prevention & control*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000235:genetics / Q000276:immunology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage* / Q000191:economics; D019259:Lamivudine / Q000008:administration & dosage* / Q000191:economics; D016031:Liver Transplantation / Q000009:adverse effects* / Q000191:economics; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D055502:Secondary Prevention; D019562:Viral Load
D000998:Antiviral Agents; D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D016756:Immunoglobulins, Intravenous; D019259:Lamivudine